Acrescent H. Lundbeck A/S · Refused · ATC N06D
Therapeutic indication (EMA)
Treatment of Alzheimers disease
Active substances
Donepezil + Memantine
- US FDA 5
- EMA 2
- US price lines 6
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NAMZARIC | 10MG;14MG; 10MG;28MG; 10MG;7MG; 10MG;21MG | capsule, extended release · oral | ABBVIE | Prescription | 23 Dec 2014 |
| MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE | 10MG;14MG; 10MG;28MG; 10MG;7MG; 10MG;21MG | capsule, extended release · oral | AMNEAL | Prescription | 27 Jan 2017 |
| MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE | 10MG;21MG | capsule, extended release · oral | ANI PHARMS | Prescription | 15 Dec 2023 |
| MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE | 10MG;14MG; 10MG;28MG | capsule, extended release · oral | MACLEODS PHARMS | Prescription | 15 Jul 2025 |
| MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE | 10MG;14MG; 10MG;28MG | capsule, extended release · oral | XIAMEN LP PHARM CO | Prescription | 15 Jul 2025 |
EMA European Union — centrally authorised medicines
Balaxur Merz Pharmaceuticals GmbH · Refused · ATC N06DA52
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MEMANTINE-DONEPEZIL ER 14-10 MG | $6.48822 | per EA | 23 Sep 2026 |
| US NADAC | MEMANTINE-DONEPEZIL ER 28-10 MG | $8.44457 | per EA | 23 Sep 2026 |
| US NADAC | NAMZARIC 14 MG-10 MG CAPSULE | $19.84763 | per EA | 23 Sep 2026 |
| US NADAC | NAMZARIC 21 MG-10 MG CAPSULE | $19.95748 | per EA | 23 Sep 2026 |
| US NADAC | NAMZARIC 28 MG-10 MG CAPSULE | $19.80435 | per EA | 23 Sep 2026 |
| US NADAC | NAMZARIC 7 MG-10 MG CAPSULE | $19.82669 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.